Incyte Showcases HS Data at AAD 2026
Incyte has announced that it will present a comprehensive set of new clinical data from its Inflammation and Autoimmunity (IAI) portfolio at the American Academy of Dermatology Annual Meeting 2026, scheduled to take place from March 27 to March 31, 2026, in Denver. The company’s presence at this major dermatology conference will highlight important advancements across multiple chronic inflammatory skin conditions, including hidradenitis suppurativa (HS), atopic dermatitis, and vitiligo.
A central focus of Incyte’s presentations will be new late-breaking data from its investigational oral therapy, povorcitinib, particularly in the treatment of hidradenitis suppurativa—a chronic, painful inflammatory skin disease characterized by recurrent nodules, abscesses, and scarring. The late-breaking findings include 54-week results from the pivotal Phase 3 STOP-HS1 and STOP-HS2 clinical trials. These studies evaluate the long-term safety and efficacy of povorcitinib in patients with moderate-to-severe HS, a population with significant unmet medical needs.
According to Jim Lee, M.D., Ph.D., Group Vice President of Inflammation and Autoimmunity at Incyte, the data represent a meaningful step forward in understanding the long-term therapeutic potential of povorcitinib. He emphasized that the 54-week results not only reinforce earlier findings but also provide robust evidence supporting sustained efficacy and a favorable safety profile over an extended treatment period. These outcomes are expected to strengthen confidence in povorcitinib as a promising treatment candidate and contribute to the continued expansion of Incyte’s IAI portfolio.
Late-Breaking Oral Presentation
The highlight of Incyte’s HS data will be featured in a late-breaking oral session titled:
“Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies.”
This presentation will take place during Session S034 – Late-Breaking Research: Session 2, on Saturday, March 28, 2026. The inclusion of this study in a late-breaking session underscores its importance and the novelty of the data being presented. These results are expected to provide valuable insights into how povorcitinib performs over a longer treatment duration, including its impact on disease severity, symptom reduction, and patient quality of life.
The STOP-HS program represents a significant milestone in HS research, as long-term data in this condition remain limited. By demonstrating sustained improvements over 54 weeks, Incyte aims to address a key gap in clinical knowledge and offer hope for more durable treatment options.
Expanded ePoster Presentations Across Dermatology
In addition to the late-breaking oral presentation, Incyte will showcase a wide range of findings through multiple ePoster presentations. These abstracts span several dermatologic conditions and include both clinical trial data and real-world insights.
Atopic Dermatitis
In the area of atopic dermatitis, Incyte will present new findings related to ruxolitinib cream, marketed as Opzelura®. This topical Janus kinase (JAK) inhibitor has already gained attention for its role in managing inflammatory skin conditions.
One ePoster will highlight how ruxolitinib cream improves patient-reported outcomes in adults with moderate atopic dermatitis, based on results from the TRuE-AD4 study. This research emphasizes not only clinical efficacy but also the importance of patient experience, including symptom relief, itch reduction, and overall quality of life improvements.
Another presentation will explore the efficacy of ruxolitinib cream across diverse patient populations. Specifically, it examines how the treatment performs regardless of baseline disease severity or prior medication history. These findings suggest that ruxolitinib cream may offer consistent benefits across a broad spectrum of patients, enhancing its utility in real-world clinical practice.
Hidradenitis Suppurativa
Beyond the late-breaking oral session, additional ePoster presentations will further explore povorcitinib’s role in HS treatment. One study will present 24-week interim Phase 3 results in patients who have previously been treated with anti-TNF therapies. This subgroup analysis is particularly important, as these patients often represent a more difficult-to-treat population.
In addition to clinical trial data, Incyte will present findings from the Global HERALD survey (Hidradenitis Suppurativa Experiences in the Real World). This large-scale survey captures both physician and patient perspectives on HS, offering a comprehensive view of disease burden, diagnostic challenges, and treatment patterns worldwide.
One HERALD-based presentation will focus on physician perspectives, shedding light on how HS is diagnosed and managed in clinical practice. It will highlight variations in treatment approaches and identify areas where additional education or resources may be needed.
Another presentation will center on patient perspectives, examining disease burden and treatment history. These insights are critical for understanding the real-world impact of HS, including its physical, emotional, and social consequences. Together, these survey-based findings complement clinical trial data by providing a more holistic understanding of the disease.
Vitiligo
In the field of vitiligo, Incyte will present new analyses related to ruxolitinib cream, further expanding its dermatology portfolio. One ePoster will explore the relationship between repigmentation and quality of life among patients treated with the cream in the TRuE-V studies. This research highlights how visible improvements in skin pigmentation can translate into meaningful psychosocial benefits for patients.
Another presentation will examine real-world factors influencing vitiligo care, based on patient survey data. This study aims to identify barriers to treatment, patient preferences, and patterns of medication use. Such insights can help guide more patient-centered care strategies and improve treatment adherence.
Strategic Importance of the IAI Portfolio
The breadth of data being presented at AAD 2026 reflects Incyte’s ongoing commitment to advancing therapies in inflammation and autoimmunity. By addressing multiple dermatologic conditions with both systemic and topical treatments, the company is building a diversified portfolio designed to meet a wide range of patient needs.
Povorcitinib, in particular, represents a key growth opportunity within this strategy. As an oral JAK inhibitor, it offers a potentially convenient and effective option for patients with moderate-to-severe inflammatory diseases. The positive long-term data from the STOP-HS program could play a crucial role in its future regulatory and commercial trajectory.
Similarly, ruxolitinib cream continues to demonstrate versatility across indications, from atopic dermatitis to vitiligo. Its ability to deliver consistent efficacy and improve patient-reported outcomes positions it as an important component of Incyte’s dermatology offerings.
In summary, Incyte’s presentations at the American Academy of Dermatology Annual Meeting 2026 will provide a comprehensive look at the company’s progress in developing innovative treatments for chronic inflammatory skin diseases. The late-breaking 54-week data for povorcitinib in hidradenitis suppurativa stand out as a major highlight, offering new evidence of long-term benefit in a challenging condition.
Complemented by a robust set of ePoster presentations across atopic dermatitis, HS, and vitiligo, the data underscore Incyte’s commitment to improving patient outcomes through both clinical research and real-world insights. As these findings are shared with the global dermatology community, they are expected to contribute to evolving treatment paradigms and support better care for patients living with these complex conditions.
About Povorcitinib
Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo nodularis (PN), as well as a Phase 2 trial for asthma.
About Opzelura® (ruxolitinib) Cream
Opzelura® (ruxolitinib) cream, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. FDA for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.
In Europe, Opzelura (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Incyte has worldwide rights for the development and commercialization of Opzelura.
Opzelura is a registered trademark of Incyte.
About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.
